Sugi Predict

Sugi Predict / Compounds / SCHEMBL5378775

SCHEMBL5378775

SCHEMBL5378775

CCc1nc(-c2ccccc2)c(-c2ccccc2)[nH]1

nearest known ligand 0.59

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 3/20 0.59
▸ HPGD P15428 3/20 0.59
▸ SMN1; SMN2 Q16637 2/20 0.59
▸ ALDH1A1 P00352 2/20 0.54
▸ L3MBTL1 Q9Y468 2/20 0.54
▸ LMNA P02545 1/20 0.54
▸ TP53 P04637 1/20 0.49
▸ MAPK13 O15264 3/20 0.49
▸ MAPK12 P53778 3/20 0.49
▸ MAPK11 Q15759 3/20 0.49
▸ MAPK14 Q16539 3/20 0.49
▸ RAF1 P04049 1/20 0.49
▸ MAPK9 P45984 1/20 0.49
▸ MAPT P10636 1/20 0.48
▸ PTGS1 P23219 1/20 0.48
▸ PTGS2 P35354 1/20 0.48
▸ NOX1 Q9Y5S8 1/20 0.47
▸ GCGR P47871 2/20 0.47
▸ SOAT1 P35610 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11189397 0.89 KDM4E (0.53) KDM4EHPGDSMN1; SMN2ALDH1A1L3MBTL1
SCHEMBL9518314 0.86 ADORA3 (0.56) KDM4EHPGDSMN1; SMN2ALDH1A1L3MBTL1
Ammonia Solution, Strong SCHEMBL27564581 0.84 ADORA3 (0.55) KDM4EHPGDSMN1; SMN2ALDH1A1L3MBTL1
SCHEMBL9515033 0.83 KDM4E (0.53) KDM4EHPGDSMN1; SMN2ALDH1A1L3MBTL1
SCHEMBL29668081 0.82 KDM4E (0.51) KDM4EHPGDSMN1; SMN2ALDH1A1L3MBTL1
SCHEMBL2050519 0.82 KDM4E (0.51) KDM4EHPGDSMN1; SMN2ALDH1A1L3MBTL1
SCHEMBL7266395 0.81 KDM4E (0.55) KDM4EHPGDSMN1; SMN2ALDH1A1L3MBTL1
SCHEMBL1696508 0.81 TP53 (0.53) KDM4EHPGDSMN1; SMN2ALDH1A1L3MBTL1
SCHEMBL1929921 0.81 KDM4E (0.55) KDM4EHPGDSMN1; SMN2ALDH1A1L3MBTL1
SCHEMBL22602362 0.81 KDM4E (0.55) KDM4EHPGDSMN1; SMN2ALDH1A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-3997552-A HERBICIDE BAYER AKTIENGESELLSCHAFT (DT) 1976-12-14 — — US claimed
CN-113891885-B Compound and organic light emitting device comprising the same 株式会社LG化学 2024-05-10 — — CN disclosed
CN-113891885-A Compound and organic light emitting device including the same 株式会社LG化学 2022-01-04 — — CN disclosed
WO-2021049843-A1 COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING SAME 주식회사 엘지화학 2021-03-18 — — WO disclosed
WO-2021049843-A1 COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING SAME 주식회사 엘지화학 2021-03-18 — — WO disclosed
US-9856478-B2 Method for selectively inhibiting ACAT1 in the treatment of obesity, metabolic syndrome, and atherosclerosis TRUSTEES OF DARTMOUTH COLLEGE (US) 2018-01-02 — — US disclosed
US-20170292128-A1 METHOD FOR SELECTIVELY INHIBITING ACAT1 IN THE TREATMENT OF NEURODEGENERATIVE DISEASES NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2017-10-12 — — US disclosed
US-20160355824-A1 METHOD FOR SELECTIVELY INHIBITING ACAT1 IN THE TREATMENT OF OBESITY, METABOLIC SYNDROME, AND ATHEROSCLEROSIS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2016-12-08 — — US disclosed
US-9388413-B2 Method for selectively inhibiting ACAT1 in the treatment of neurodegenerative diseases TRUSTEES OF DARTMOUTH COLLEGE (US) 2016-07-12 — — US disclosed
US-9388414-B2 Method for selectively inhibiting ACAT1 in the treatment of neurodegenerative diseases TRUSTEES OF DARTMOUTH COLLEGE (US) 2016-07-12 — — US disclosed
US-20020188009-A1 Bisarylimidazolyl fatty acid amide hydrolase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2002-12-12 — — US disclosed
WO-2002087569-A1 BISARYLIMIDAZOLYL FATTY ACID AMIDE HYDROLASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2002-11-07 — — WO disclosed
EP-0365907-B1 Process for the preparation of p-nitrophenyl imidazoles BASF AG (DE) 1993-12-22 — — EP disclosed
US-5008398-A Preparation of p-nitrophenyl-imidazoles BASF AKTIENGESELLSCHAFT (DE) 1991-04-16 — — US disclosed
EP-0392160-A1 Azole-1-alkanamides as antiarrhythmic agents and preparation thereof STERLING DRUG INC. (US) 1990-10-17 — — EP disclosed
US-4962120-A ANTIARRHYTHMIA AGENTS STERLING DRUG INC. (US) 1990-10-09 — — US disclosed
US-4756994-A Ethylenically unsaturated monomer, photopolymerizable monomer, polymerization inhibitor, nitrogen-containing compound SEKISUI KAGAKU KOGYO KABUSHIKI KAISHA (JP) 1988-07-12 — — US disclosed
EP-0206030-A2 Photocurable composition SEKISUI KAGAKU KOGYO KABUSHIKI KAISHA (JP) 1986-12-30 — — EP disclosed
US-4410706-A Preparation of 2-vinylimidazoles by dehydrogenation of 2-ethylimidazoles and 2-ethylimidazolines AMERICAN CYANAMID COMPANY (US) 1983-10-18 — — US disclosed
US-3997552-A HERBICIDE BAYER AKTIENGESELLSCHAFT (DT) 1976-12-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170292128-A1 METHOD FOR SELECTIVELY INHIBITING ACAT1 IN THE TREATMENT OF NEURODEGENERATIVE DISEASES ACAT2, ACAT1, ACACB KDM4E 2570/4885HPGD 3098/4885SMN1; SMN2 679/4885
US-20020188009-A1 Bisarylimidazolyl fatty acid amide hydrolase inhibitors FAAH, FAAH2, FASN KDM4E 2584/4885HPGD 510/4885SMN1; SMN2 4026/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.